Scale-up of a novel hyaluronan-based delivery system

新型透明质酸递送系统的放大

• 批准号: 548822-2020
• 负责人: Shoichet, Molly
• 金额: $ 9.11万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=700572
• 关键词: Scale; up; novel; hyaluronan; based

A hydrogel platform was engineered to provide sustained release of biomolecules. The product addresses an unmet need in the post-operative pain market and will provide extended pain-relief to the user. This proposal focuses on optimizing the formulation for sustained release based on a series of design criteria, scale-up manufacturing, sterility and stability. We propose to build on a successful phase I I2I where we formed and financed AmacaThera with $4.7million in seed capital. In this phase IIb I2I proposal, we aim to advance the manufacturing and scale-up of a product designed for post-operative pain to ensure that we can manufacture at scale a uniform product, with controlled release attributes that is both sterile and stable on the shelf. This proposal is a strong academic-industry partnership between The Shoichet Lab and AmacaThera, taking advantage of research excellence from the Shoichet lab and business acumen from AmacaThera.

设计水凝胶平台以提供生物分子的持续释放。该产品解决了术后疼痛市场中未满足的需求，并将为用户提供延长的疼痛缓解。该提案重点关注基于一系列设计标准、规模化生产、无菌性和稳定性优化缓释制剂。 我们建议在成功的第一阶段I2 I的基础上建立，在该阶段，我们成立了AmacaThera，并以470万美元的种子资本为AmacaThera提供资金。在本IIb I2 I阶段提案中，我们的目标是推进针对术后疼痛设计的产品的生产和规模扩大，以确保我们可以大规模生产具有控释属性的统一产品，该产品在货架上既无菌又稳定。 该提案是Shoichet实验室和AmacaThera之间强大的学术-行业合作伙伴关系，利用Shoichet实验室的卓越研究和AmacaThera的商业智慧。